Browse SMC3

Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Chromosome Chromosome, centromere Note=Associates with chromatin. Before prophase it is scattered along chromosome arms. During prophase, most of cohesin complexes dissociate from chromatin probably because of phosphorylation by PLK, except at centromeres, where cohesin complexes remain. At anaphase, the RAD21 subunit of the cohesin complex is cleaved, leading to the dissociation of the complex from chromosomes, allowing chromosome separation. The phosphorylated form at Ser-1083 is preferentially associated with unsynapsed chromosomal regions (By similarity).
Domain PF06470 SMC proteins Flexible Hinge Domain
PF02463 RecF/RecN/SMC N terminal domain
Function

Central component of cohesin, a complex required for chromosome cohesion during the cell cycle. The cohesin complex may form a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. Cohesion is coupled to DNA replication and is involved in DNA repair. The cohesin complex plays also an important role in spindle pole assembly during mitosis and in chromosomes movement.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000819 sister chromatid segregation
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006275 regulation of DNA replication
GO:0007052 mitotic spindle organization
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007064 mitotic sister chromatid cohesion
GO:0007067 mitotic nuclear division
GO:0007126 meiotic nuclear division
GO:0008156 negative regulation of DNA replication
GO:0010948 negative regulation of cell cycle process
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0019827 stem cell population maintenance
GO:0032875 regulation of DNA endoreduplication
GO:0032876 negative regulation of DNA endoreduplication
GO:0042023 DNA endoreduplication
GO:0044786 cell cycle DNA replication
GO:0045786 negative regulation of cell cycle
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051321 meiotic cell cycle
GO:0090329 regulation of DNA-dependent DNA replication
GO:0098727 maintenance of cell number
GO:0098813 nuclear chromosome segregation
GO:1903046 meiotic cell cycle process
GO:2000104 negative regulation of DNA-dependent DNA replication
Molecular Function GO:0003682 chromatin binding
GO:0003774 motor activity
GO:0003777 microtubule motor activity
GO:0036033 mediator complex binding
GO:0045502 dynein binding
GO:0046982 protein heterodimerization activity
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000785 chromatin
GO:0000793 condensed chromosome
GO:0000794 condensed nuclear chromosome
GO:0000795 synaptonemal complex
GO:0000798 nuclear cohesin complex
GO:0000800 lateral element
GO:0000922 spindle pole
GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005819 spindle
GO:0008278 cohesin complex
GO:0008280 cohesin core heterodimer
GO:0016363 nuclear matrix
GO:0030893 meiotic cohesin complex
GO:0034399 nuclear periphery
GO:0034991 nuclear meiotic cohesin complex
GO:0044420 extracellular matrix component
GO:0044454 nuclear chromosome part
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa04110 Cell cycle
hsa04114 Oocyte meiosis
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2470946: Cohesin Loading onto Chromatin
R-HSA-2468052: Establishment of Sister Chromatid Cohesion
R-HSA-68886: M Phase
R-HSA-1500620: Meiosis
R-HSA-1221632: Meiotic synapsis
R-HSA-392499: Metabolism of proteins
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-68884: Mitotic Telophase/Cytokinesis
R-HSA-597592: Post-translational protein modification
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-69242: S Phase
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-3108214: SUMOylation of DNA damage response and repair proteins
R-HSA-2467813: Separation of Sister Chromatids
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SMC3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SMC3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.55 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SMC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0960.684
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1670.931
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2930.843
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0780.836
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1040.96
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0460.986
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1770.661
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1460.937
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2550.899
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7990.559
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3170.512
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2320.000455
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SMC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SMC3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SMC3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SMC3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SMC3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SMC3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SMC3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSMC3
Namestructural maintenance of chromosomes 3
Aliases SMC3L1; bamacan; bamacan proteoglycan; CSPG6; chondroitin sulfate proteoglycan 6 (bamacan); CDLS3; HCAPL1; S ......
Chromosomal Location10q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SMC3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.